Sort by
Keyphrases
Clinical Trials
100%
Risk-benefit
81%
Risk Outcomes
75%
Patient Benefit
75%
Patient Risk
75%
Patient Outcomes
75%
Drug Development
75%
Randomized Controlled Trial
36%
Health Inequities
26%
Scoping Review
26%
Adverse Events
22%
Female Mice
21%
Sex Differences
19%
Inequity
19%
Patient-reported Outcomes
17%
Blood Pressure
17%
FDA-approved Drugs
17%
Objective Response Rate
17%
PubMed
17%
Male Mice
16%
Overall Survival
15%
Embase
15%
High Salt
14%
Urology
14%
Sectional Analysis
13%
Benign Prostatic Hyperplasia
13%
Fragility Analysis
13%
American Urological Association
13%
High-fructose Diet
13%
Ramucirumab
13%
Approved Indication
12%
Reporting Quality
10%
Fragility Index
10%
MEDLINE
10%
Cochrane
10%
Progression-free Survival
9%
Trial Characteristics
8%
Dialysis Care
8%
Olaparib
8%
Surgical Management
8%
Major Depressive Disorder
8%
Meta-epidemiological Study
8%
Person-centered Language
8%
Urinary Protein Excretion
8%
High-protein Diet
8%
Stress Urinary Incontinence
8%
Stress Management
8%
Lenvatinib
8%
Regorafenib
8%
Afatinib
8%
Pharmacology, Toxicology and Pharmaceutical Science
Clinical Trial
98%
Drug Development
84%
Adverse Event
32%
Malignant Neoplasm
30%
Overall Survival
22%
Progression Free Survival
19%
Ramucirumab
13%
Olaparib
8%
Cross Sectional Study
8%
Lenvatinib
8%
Afatinib
8%
Regorafenib
8%
Trametinib
8%
Dabrafenib
8%
Sorafenib
8%
Breast Cancer
7%
Randomized Controlled Trial
7%
Monotherapy
6%
Health Disparity
6%
Solid Malignant Neoplasm
6%
Pharmaceutical Manufacturing
6%
Medicine and Dentistry
Clinical Trial
55%
Randomized Controlled Trial
33%
Cross Sectional Study
24%
Systematic Review
18%
Blood Pressure
17%
Table Salt
17%
Urology
14%
Patient-Reported Outcome
13%
High-Fructose Diet
13%
Prostate Hypertrophy
13%
Ramucirumab
13%
Adverse Event
11%
Sex Difference
10%
Olaparib
8%
Major Depressive Episode
8%
Rural Population
8%
Kidney Transplantation
8%
Fructose
8%
Human Subject
7%
Malignant Neoplasm
7%
Overall Survival
7%
General Medicine
6%
Health Disparity
6%
Nutrition
6%
Logistic Regression Analysis
6%
Mean Arterial Pressure
6%
Meta-Analysis
6%
Progression Free Survival
5%
Transgender
5%
